Double Bond Pharmaceutical Competitors and Similar CompaniesClear all
Double Bond Pharmaceutical's competitors and similar companies include Turning Point Therapeutics, NATCO Pharma, Pharmstandard and AbelZeta.
 Double Bond Pharmaceutical Double Bond Pharmaceutical is a company that develops approaches for treatment of cancers. |  Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases. |  NATCO Pharma NATCO Pharma is a company focused on research, manufacturing, and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (API). |  Pharmstandard Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products. |  AbelZeta AbelZeta (formerly known as Cellular Biomedicine Group) is a biopharmaceutical company that develops therapeutic solutions. | |
Founding Date | Founding Date 2014 | Founding Date 2013 | Founding Date 1981 | Founding Date 2003 | Founding Date 2009 |
Type | Type Public | Type Subsidiary | Type Public | Type Subsidiary | Type Private |
Tags | |||||
Locations | Locations Uppsala, SE HQ Uppsala, SE | Locations San Diego, US HQ | Locations Hyderabad, IN HQ Central Hope Town, IN Chennai, IN Hyderabad, IN Santola, IN Vijayapuri North, IN | Locations Dolgoprudny, RU HQ Kursk, RU Moscow, RU Petrovo Dalnee, RU Tomsk, RU Ufa, RU Vol'ginskii, RU | Locations Rockville, US HQ Shanghai, CN |
Employees | Employees 1318% increase | Employees 474% decrease | Employees 4,016 | Employees 1,77814% increase | Employees 1261% decrease |
Financial | |||||
Revenue (est.) | Revenue (est.) kr84k (FY, 2025) | Revenue (est.) $30.8m (FY, 2021) | Revenue (est.) ₹44.1b (FY, 2025) | Revenue (est.) ₽152.1b (FY, 2024) | Revenue (est.) N/A |
Cost of goods | Cost of goods kr125k (FY, 2025) | Cost of goods N/A | Cost of goods ₹7.5b (FY, 2025) | Cost of goods ₽117b (FY, 2024) | Cost of goods N/A |
Gross profit | Gross profit (kr25k) (FY, 2025) | Gross profit N/A | Gross profit ₹37b (FY, 2025) | Gross profit ₽35.2b (FY, 2024) | Gross profit N/A |
Net income | Net income (kr333k) (FY, 2025) | Net income ($236.6m) (FY, 2021) | Net income ₹18.8b (FY, 2025) | Net income ₽22.7b (FY, 2024) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised $ 81.7k | Total funding raised $ 144.4m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Turning Point Therapeutics
HQ
San Diego, US
Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.
View companyNATCO Pharma
HQ
Hyderabad, IN
Employees
4,016
NATCO Pharma is a company focused on research, manufacturing, and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (API).
View companyPharmstandard
HQ
Dolgoprudny, RU
Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products.
View companyAbelZeta
HQ
Rockville, US
Employees
126↓ 1% decrease
AbelZeta (formerly known as Cellular Biomedicine Group) is a biopharmaceutical company that develops therapeutic solutions.
View company